Fulcrum Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.38) Per Share (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Investment analysts at HC Wainwright lifted their Q3 2024 earnings per share (EPS) estimates for Fulcrum Therapeutics in a research note issued on Thursday, August 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.43). HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($1.14) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at $0.13 EPS and FY2028 earnings at $0.58 EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%.

Other equities research analysts have also issued reports about the company. Oppenheimer decreased their price target on Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, May 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $23.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, July 10th. Finally, The Goldman Sachs Group raised shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $6.00 to $15.00 in a research note on Monday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $15.57.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $8.87 on Monday. The firm has a market capitalization of $553.49 million, a PE ratio of -5.57 and a beta of 2.29. The business has a 50 day simple moving average of $7.60 and a two-hundred day simple moving average of $8.24. Fulcrum Therapeutics has a 1 year low of $3.14 and a 1 year high of $13.70.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FULC. China Universal Asset Management Co. Ltd. raised its holdings in shares of Fulcrum Therapeutics by 348.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,150 shares of the company’s stock valued at $48,000 after acquiring an additional 5,556 shares in the last quarter. abrdn plc purchased a new position in Fulcrum Therapeutics during the 4th quarter valued at about $1,734,000. Capstone Investment Advisors LLC bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $68,000. Affinity Asset Advisors LLC purchased a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $844,000. Finally, Vestal Point Capital LP bought a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at approximately $6,919,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.